Guaifenesin Dosing Guidelines
For adults and children ≥12 years, the recommended dose of immediate-release guaifenesin is 200–400 mg every 4 hours, not exceeding 2400 mg in 24 hours (maximum 6 doses per day); for children 6 to <12 years, 100–200 mg every 4 hours; for children 2 to <6 years, 50–100 mg every 4 hours; and for children <2 years, consult a physician. 1
Standard Immediate-Release Dosing by Age
Adults and Adolescents (≥12 years)
- Dose: 200–400 mg (10–20 mL of oral solution) every 4 hours 1
- Maximum: 2400 mg per 24 hours (6 doses) 1
- The flexible dosing range allows titration to achieve adequate plasma concentrations while maintaining safety 2
Children 6 to <12 Years
- Dose: 100–200 mg (5–10 mL of oral solution) every 4 hours 1
- Maximum: 1200 mg per 24 hours (6 doses) 1
Children 2 to <6 Years
Children <2 Years
- Recommendation: Consult a physician before use 1
- Guaifenesin is not FDA-approved for this age group without medical supervision 1
Extended-Release Formulations
Adults and Adolescents (≥12 years)
- Dose: 600–1200 mg every 12 hours 3
- Extended-release tablets provide equivalent steady-state exposure to immediate-release formulations dosed every 4 hours, with the convenience of twice-daily dosing 3
- The 1200 mg twice-daily dose is bioequivalent to 400 mg immediate-release every 4 hours 3
Food Effects
- Extended-release guaifenesin can be taken with or without food, though time to maximum concentration (Tmax) may be delayed in the fed state without affecting overall bioavailability 3
Pharmacokinetic Considerations in Children
- Guaifenesin pharmacokinetics in children aged 2–17 years demonstrate age-related increases in oral clearance and volume of distribution due to increasing body size 4
- When comparing the upper recommended dose for children 2–11 years with the lower dose for adolescents 12–17 years, similar systemic exposure is achieved, supporting the age-based dosing recommendations 4
- Allometric scaling indicates no maturation-related changes in clearance or volume of distribution beyond body size effects 4
Clinical Efficacy Context
Evidence for Use
- Guaifenesin is indicated as an expectorant for relief of wet cough and chest congestion in acute upper respiratory tract infections and stable chronic bronchitis 2
- Clinical efficacy has been demonstrated most consistently in chronic respiratory conditions where mucus production and cough are stable symptoms 2
Limitations of Evidence
- A single 1200 mg dose of extended-release guaifenesin did not significantly affect mucociliary clearance, cough clearance, or sputum biophysical properties compared to placebo in adults with acute respiratory tract infections 5
- Recent systematic reviews question the magnitude of benefit over placebo for upper respiratory symptoms 6
- Despite widespread use, high-quality evidence supporting guaifenesin's expectorant effect in acute respiratory infections remains limited 2, 6
Common Pitfalls and Recommendations
- Exceeding maximum daily dose: Strict adherence to the 6-dose-per-day limit (every 4 hours for immediate-release) is essential to avoid toxicity 1
- Inappropriate use in children <2 years: Always obtain physician guidance before administering to infants and toddlers 1
- Confusing immediate-release and extended-release dosing: Extended-release formulations require 12-hour intervals, not 4-hour intervals 3
- Expecting rapid symptom relief: Multiple daily doses are needed to maintain therapeutic effect with immediate-release formulations due to guaifenesin's short half-life 2, 3
- Using as monotherapy for bacterial infections: Guaifenesin provides symptomatic relief only and should not replace antibiotics when bacterial pneumonia is diagnosed 7